What is CAMP4 THERAPEUTICS CORPORATION's (CAMP) StockRank?

MoatMap's StockRank for CAMP4 THERAPEUTICS CORPORATION (CAMP) is 13/100, with a Strong Sell signal. This is a composite score combining Quality (27), Value (31), and Momentum (42) factor ranks across MoatMap's 19,000+ stock universe.

Does CAMP4 THERAPEUTICS CORPORATION have an economic moat?

CAMP4 THERAPEUTICS CORPORATION (CAMP) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is CAMP4 THERAPEUTICS CORPORATION a buy, hold, or sell?

MoatMap's current signal for CAMP4 THERAPEUTICS CORPORATION (CAMP) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is CAMP4 THERAPEUTICS CORPORATION in?

CAMP4 THERAPEUTICS CORPORATION (CAMP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CAMP

STRONG SELLREMOVE

CAMP4 THERAPEUTICS CORPORATION · Healthcare · United States · $233M · Avg Vol: $331K/d

StockRank

P/E (TTM)

—

ROE

-209.3%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

CAMP4 Therapeutics is a recently listed clinical-stage biotechnology company focused on RNA therapeutics, representing a highly speculative asset with no current revenues or established moat.

COMPANY DESCRIPTION

CAMP4 THERAPEUTICS CORPORATION is a biotechnology company developing a new class of RNA-targeting therapeutics designed to upregulate gene expression. Operating in the nascent and high-potential field of RNA modulation, CAMP4 aims to address diseases by precisely controlling gene expression with novel small molecule approaches. This clinical-stage biotech company leverages its proprietary RNA-targeting platform to develop first-in-class treatments for severe diseases.

FINANCIAL SUMMARY

Year	2022	2023	2024	CAGR
Revenue	0	350,000	652,000	86.3%
EPS	-3.64	-4.07	-11.04	—
Shares	20M	20M	20M	+3.4%
Debt	12M	12M	9M	-16.5%
Equity	-78M	-124M	63M	—
Op CF	-39M	-44M	-46M	—
Inv CF	-4M	-678,000	-441,000	—
Fin CF	100M	301,000	72M	—

PRICE (1M)+3.5%

SMA 50SMA 200

$4.19

RSI (14)

43.3

52W High

$7.75

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-50.9%13.7

ROE

-209.3%3.4

GP/Assets

-29.1%3.4

Op. Margin

-1010.1%7.1

FCF/Assets

-11.7%26.0

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.07x71.1

Current Ratio

6.15x76.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.4x68.0

P/FCF

—N/A

P/B

7.0x16.6

P/S

55.3x9.8

Div Yield

—N/A

Momentum

52W High %

54%29.0

RS 6M

-35%34.4

SMA 50/200

1.03x68.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+69%62.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$233M

P/E (Forward)

-5.7x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAMP are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CAMP	CAMP4 THERAPEUTICS CORPORATION(you)	$233M	13	STRONG SELL
KROS	Keros Therapeutics, Inc.	$225M	14	STRONG SELL
TRDA	Entrada Therapeutics, Inc.	$265M	13	STRONG SELL
RNA	Atrium Therapeutics, Inc.	$229M	17	STRONG SELL
FHTX	Foghorn Therapeutics Inc.	$251M	16	STRONG SELL
VYGR	Voyager Therapeutics, Inc.	$236M	17	STRONG SELL
CHRS	Coherus Oncology, Inc.	$255M	17	STRONG SELL
CNTX	Context Therapeutics Inc.	$260M	16	STRONG SELL
KRRO	Korro Bio, Inc.	$193M	12	STRONG SELL
ALEC	Alector, Inc.	$239M	8	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

CAMP4 THERAPEUTICS CORPORATION (CAMP) — Stock Score Summary

CAMP4 THERAPEUTICS CORPORATION (CAMP) has a MoatMap StockRank of 13/100 based on Quality (27/100), Value (31/100), and Momentum (42/100) factor scores. The current signal is STRONG SELL. CAMP4 Therapeutics is a recently listed clinical-stage biotechnology company focused on RNA therapeutics, representing a highly speculative asset with no current revenues or established moat.

Key Financial Metrics

Price	$4.19
Market Cap	$233M
P/E (Forward)	-5.72
Price/Book	7.04
Return on Equity	-209.3%
Return on Invested Capital	-50.9%
Debt/Equity	6.87
Gross Margin	0.0%
Operating Margin	-1010.1%
Revenue Growth	50.8%
Free Cash Flow	$-14M

CAMP4 THERAPEUTICS CORPORATION operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is CAMP4 THERAPEUTICS CORPORATION’s (CAMP) StockRank?: MoatMap’s StockRank for CAMP4 THERAPEUTICS CORPORATION (CAMP) is 13/100, with a Strong Sell signal. It is a composite of Quality (27), Value (31), and Momentum (42) factor ranks across MoatMap’s 19,000+ stock universe.
Does CAMP4 THERAPEUTICS CORPORATION have an economic moat?: CAMP4 THERAPEUTICS CORPORATION (CAMP) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is CAMP4 THERAPEUTICS CORPORATION a buy, hold, or sell?: MoatMap’s current signal for CAMP4 THERAPEUTICS CORPORATION (CAMP) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is CAMP4 THERAPEUTICS CORPORATION in?: CAMP4 THERAPEUTICS CORPORATION (CAMP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).